Research Roundup, November 2025

In this month’s roundup, we highlight recent studies and announcements related to eosinophil-associated diseases:

Benralizumab Reduces HES Flare in Phase 3 Trial

In November, AstraZeneca announced full results from the NATRON Phase 3 trial for hypereosinophilic syndromes (HES). In the trial, adults with HES were randomized to receive 30 mg injection of Fasenra® (benralizumab), given as a single injection under the skin once a month, or placebo every for weeks. The study showed that the drug significantly reduced the chance of having a flare by about 65% compared to placebo. In addition, those receiving the drug had fewer flares and less fatigue than those on placebo. The side effects were about the same between the two groups.  These findings suggest that benralizumab may offer a promising, once-monthly treatment option for adults with HES.

Updates from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Study Looks at Particulate Matter as Possible Risk Factor for EoE

A large case-control study published in Frontiers in Allergy linked a national pathology database with county-level air pollution data to see whether long-term exposure to particulate matter was associated with eosinophilic esophagitis (EoE). The authors found only very modest increases in EoE odds at higher particulate levels, suggesting that if particulate matter contributes to EoE risk, its effect is likely small.

Weight Gain Associated with Decreased Treatment Response to EoE Dietary Therapy

A new publication in Gastro Hep Advances looks at the association of weight gain with lack of treatment response to dietary therapy over time in adults with eosinophilic esophagitis (EoE).  One of the postulates of the study was that as people feel better and perhaps eat more, they may gain weight and become less adherent to their treatments. However, the exact reason that weight gain may be associated with less response is not entirely clear.